arXiv:1410.3768v1 [physics.med-ph] 14 Oct 2014

Stochastic model for computer simulation of the number of cancer cells and lymphocytes in homogeneous sections of cancer tumors

Arnulfo Castellanos Moreno, Alejandro Castellanos Jaramillo, Adalberto Corella, Madueño,
Sergio Gutiérrez López, Rodrigo Arturo Rosas Burgos
Departamento de Física, Universidad de Sonora, 83000, Hermosillo, Sonora, MEXICO

Abstract

We deal with a small enough tumor section to consider it homogeneous, such that populations of lymphocytes and cancer cells are independent of spatial coordinates. A stochastic model based in one step processes is developed to take into account natural birth and death rates. Other rates are also introduced to consider medical treatment: natural birth rate of lymphocytes and cancer cells; induced death rate of cancer cells due to self-competition, and other ones caused by the activated lymphocytes acting on cancer cells. Additionally, a death rate of cancer cells due to induced apoptosis is considered. Weakness due to the advance of sickness is considered by introducing a lymphocytes death rate proportional to proliferation of cancer cells.

Simulation is developed considering different combinations of the parameters and its values, so that several strategies are taken into account to study the effect of anti-angiogenic drugs as well the self-competition between cancer cells. Immune response, with the presence of a kind of specialized lymphocytes, is introduced such that they appear once cancer cells are detected. Induced apoptosis of cancer cells is introduced to model the action of several drugs under development right now. Besides, the model predicts the cancer relapse even from a very small number of cells. Simulation is done by using Gillespie algorithm.

Keyword: Noise; mathematical models; cancer; tumors.

PACS: 02.50.Ey; 05.40.-a; 87.10.+e

I. INTRODUCTION

The basic goal of this paper is to present a computer simulated model to study the population time evolution of two interacting species: cancer cells and lymphocytes, both confined in a very small tumor, such that spatial dependence does not need to be considered. Several strategies to attack the disease are simulated and two important conclusions are reached: the first one, the efficiency is enhanced with a combination of anti-angiogenic drugs plus a system based in artificial apoptosis of cancer cells; and the second one, a small amount of cancer cells are enough for the reappearance of the disease.

Efforts to capture in a mathematical model the dynamic of chemical substances and cells involved in the development of cancerous tumor started, at least, since 1955 with a work about the cell structure of lung cancer under radiotherapy [1]. After 1980 the amount of papers dealing with cell dynamics related to cancerous tumors rose significantly (See for example [2–5]).

At first, a set of cancerous cells is an avascular tissue, without blood vessels, and its dimension is just a few millimeters. Due to the lack of nutrients, the internal shells of the tumor die, then, a segregation of chemical substances produce vasculogenesis in the neighborhood of the small tumor, such that new vessels appear connecting it with the cardiovascular system. Once that food is available, the tumor grows to be an encapsulated tumor or a malignant one with capacity to spread to neighboring organs. This is known as metastasis.

Vascularization produces layers that randomly raise a barrier to block drugs introduced inside the body to destroy cancerous cells. So, the application of chemical substances becomes a spatial process where diffusion through a chaotic tissue is very hard because the administered drug must survive for internal mechanism used by living tissues disintoxicate themselves. For this reason, it is difficult to penetrate a solid tumor preserving the level of toxicity needed to kill cancerous cells [6].

Models to mathematically understand this problem has been directed to several goals. One of these is to understand how a cytotoxic substance jumps the barrier to reach cancerous cells [7]. Another one is to study the volumetric growth of the tumor after the action of chemotherapy and surgery [8]. If someone is going to develop a mathematical model to study tumors, a good advice is to take into account the classification presented by T.

Roose et. al. [9]. They say that there are three different stages for cancer development: avascular, vascular and metastatic. In the second one the tumor has blood vessels, while in the first one has not. Once that there is enough blood, solid tumors changes a lot of his properties and show several pathological features. They are disorganized and its vasculature does not work. In this cases mathematical models based on spatial diffusion processes are needed (see for example Eugene J. Koay et. al.[10]) Besides, new approaches have been introduced to predict the size of tumors based on the mitotic/apoptotic index and on diffusion penetration [11]. In the same sense, Jennifer Pascal et. al. have proposed a model based in a differential equation of diffusion inside the tumor, obtaining a biophysical description of the vascular/tissue architecture and drug perfusion within the malignant zone [12]. In summary, metastatic stage appears when cancer cells spread from the tumor to other parts of the body. Models for avascular tumors are considered as a first step toward building models for vascularized tumors. On the other hand, one should consider that when cancer cells are in a high nutrient environment they proliferate, but in low nutrient levels they die. Besides, there is an intermediate period called quiescent in which nutrient levels do not permit proliferation but cancer cells stay alive. Since any tumor needs blood to grow, a lot of research to find how to stop angiogenesis (the process of building new blood vessels from the surrounding body to the tumor) has been done. The nature of initial considerations can be seen at [13]. So, in 2008 Shaked et. al. [14] reached the conclusion that clinical trials have indicated that drugs that inhibit the growth of blood vessels can sometimes enhance the effectiveness of traditional chemotherapy. For example, simultaneous administration of the antiangiogenic drug bevacizumab with the chemotherapeutic agent paclitaxel improves survival benefits for metastatic breast cancer and small cell lung cancer. This kind of combined strategy suggests that it would be a good strategy to combine chemotherapy with antiangiogenic drugs.

Based on these findings, we simplify our problem dealing with a tumor before metastasis, so that population does not depend on spatial coordinates. As a consequence, it is possible to work with a model based in computer simulations with birth and death probabilities whose mathematical form takes into account the number of cells acting in a small volume. This approach is similar to the one consisting of working with particles in statistical physics to get thermodynamics, fluctuations and out of equilibrium phenomena, including systems with few particles like that of nanostructures. In a previous paper [15] we used the same

hypothesis to develop an analytical stochastic model where treatments based on chemotherapy were considered, and the same mathematical approach can be generalized to deal with antiangiogenic drugs, including a kind of artificially induced apoptosis in cancer cells. Two coupled and nonlinear differential equations were found to describe the temporal evolution of the average density of cancer cells and lymphocites. Numerical solutions were obtained to explore the dynamical behavior of the system. The existence of two basins was found in that paper: one where the patient survives (health basin) plus other where he dies. Just as medical evidence show us. However, by studying the random behavior around the deterministic values, a possible noise-induced escape from health basin was detected, because by evaluating the eigenvalues of the involved matrices, it can be found that random fluctuations have unbounded standard deviations, suggesting that disease could appear again. However, just linear noise was considered because the analytical approach is based on van Kampen omega expansion, and that kind of phenomena cannot be studied. A similar problem appears if we want to deal with small populations. Therefore, we have developed the present approach to explore that problem and to simulate the combination of treatments based on different strategies.

This paper is organized as follows: a model of the interaction between lymphocytes and cancer cells is presented in the second section to estimate conditions needed to consider a stationary situation, such that the number of both populations have the same number of individuals. Our attention is paid on very small tumors (or a patch of a big one) to maintain independence of spatial coordinates. A brief discussion about rate growth for cancer cells and lymphocytes is presented in the third section to explain how the basic parameters were selected. The model and the construction of transition rates is presented in the fourth section, and also a summary of a first analytical approach developed by the authors is included to show why computer simulations are needed to go ahead in the understanding of the problem. Section five is devoted to present the Gillespie algorithm, such that a reader with some experience can reproduce this work. Computational results are presented in the sixth section, and also the development with the absence and the presence of specialized defense is considered and compared. On the other hand, the effect of many no specialized lymphocytes is considered to explore what happen if the process of maturity of lymphocytes does not give the tools to identify cancer cells. Besides, strategies based on antiangiogenic drugs are studied too. Results about released patients, declared free of disease under macroscopic con-

siderations, are shown to explain that it is true that random fluctuations have unbounded standard deviations which can produce a patient suffers a relapse. A combined strategy, such that antiangiogenic and artificially induced apoptosis in cancer cells, is discussed to see that results are better, preserving a better condition of patients. Finally, conclusions are presented.

II. MATERIALS AND METHODS

In order to determine the size and the number of individuals to take into account in the simulation, we consider the picture given by Macklin et. al. [16]. They say that an avascular tumor can reach only a few micrometers of diameter when it is feeding from the natural blood vessels of the near region of the organism. By simulating the development of a tumor, they found that a quiescent core forms at about 9 days, when the tumor radius is approximately $0.34mm$, while a necrotic core appears around day 15 when the radius of tumor is approximately $0.5mm$. Therefore, to deal with a lower bound, in this paper we have considered a small tumor, such that its radius is just $r_T \simeq 200\mu m = 0.2mm$. We assume that this tumor has a very small central core of necrotized tissue due to the absence of blood irrigation. At this stage of the tumor development, the available blood vessels are just the usual density of capillaries in a healthy tissue, without any addition in capacity to irrigate that part. When the amount of blood is not enough, the cancer cells start to die due to the shortage of oxygen and nutrients. At the same time the pressure executed by the growing tumor on the surrounding healthy tissue destroys the extracellular matrix and changes the normal flux of blood. Previous to metastasis, cancer cells produce chemical substances such that the body starts the production of new vessels going to the tumor, and once this goal is reached, a new stage is initiated where cancer cells have a faster reproduction and their growing number is warrantied. Our goal is to study the tumor before metastasis starts.

So, our model is developed by assuming several hypotheses: 1) there is a stage where cancer cells are organized inside a small sphere, without the typical chaotic growth of a tumor producing metastasis, such that cancer cells form a battle line waiting for lymphocytes advancing against them through the normal vessels of the body. 2) It is assumed that no shell exists yet, so that immune system of the body can reach the cancer cells to destroy them. 3) Finally, surviving cells and destroyed extracellular matrix are not considered between cancer

cells, such that they can be considered like little spheres inside the tumor.

Therefore, the estimation of the number of cells involved can be done by taking into account geometric considerations. The volume of the blood inside some part of the body can be estimated by using the next proportion: first, a human body weighting $85kg$ has an average of 5 l of blood, so that we can assume that the percentage of blood in some place of the tissue is of the order of $c = \frac{5}{85} = 0.05882\,4$. On the other hand, the blood flow speed in a body is such that at "aorta" has an average of 40 to $50\frac{cm}{s}$, while at capillaries is just as slow as $v_{blood} = 0.03\frac{\text{cm}}{\text{s}} = 300\frac{\mu\text{m}}{\text{s}}$ (see for example [17]). With this assumption, we will get a superior bound for time to be estimated, because a study done by K. Yamauchi et. al. [18] have shown that cells migration through capillaries is such that the minimum diameter to allow migration is $8\,\mu$m, with a speed of cancer cells approximated to $48.3\frac{\mu\text{m}}{\text{h}}$. In the quicker cases, the biggest migration velocity was reached just by 20 cells with $13.2\frac{\mu\text{m}}{\text{h}}$.

Then, we consider a cylinder of area A and height $h = v_{blood} * t$ containing a volume of blood given by

$$V_{blood} = Av_{blood}tc \tag{1}$$

The number of leukocytes in the volume V_{blood} can be found by considering that its average density is

$$5 * 10^9 \frac{leukocytes}{\text{l}} \leq \rho_{leu} \leq 1.1 * 10^{10} \frac{leukocytes}{\text{l}}. \tag{2}$$

Once these considerations are done, we can formulate the next question: how many cancer cells are in touch with lymphocytes? To know that, we choose a small spheroidal tumor whose radius is r_T, containing cancer cells with radius r_c.



Figure 1

The cross section of the tumor presented to blood flow is a half of the total surface of the sphere, $A_c = 4\pi r_T^2$, containing N_c malignant cells in its boundary in potential contact with

blood. Since these cells present a half of their surface to the blood flow, we obtain that

$$N_c = \frac{\frac{1}{2}A_T}{\frac{1}{2}A_c} = \frac{\frac{1}{2}\left(4\pi r_T^2\right)}{\frac{1}{2}\left(4\pi r_c^2\right)} = \left(\frac{r_T}{r_c}\right)^2. \tag{3}$$

Besides, we need to answer the next question: how many lymphocytes can be in touch with cancer cells? This quantity is estimated by assuming that blood vessels going to the tumor are inside a cylinder whose area is $A = \pi r_T^2$ and its volume is given by

$$V_{body} = Av_b t, \tag{4}$$

with t a time which be determined ahead. The volume of blood contained in this cylinder is

$$V_{blood} = \left(Av_b t\right) c. \tag{5}$$

The amount of lymphocytes in the cylinder is

$$N_{lin} = \left(Av_b tc\right) \rho_{leu}. \tag{6}$$

We consider a system whose initial conditions are $N_{lin}\left(t=0\right) = N_c\left(t=0\right)$, so that

$$Av_b tc\rho_{leu} = \left(\frac{r_T}{r_c}\right)^2 \tag{7}$$

and

$$t = \frac{\left(\frac{r_T}{r_c}\right)^2}{Av_b c\rho_{leu}}. \tag{8}$$

Since lymphocytes are present in the scenario as a component of blood flow, and we have chosen to deal with an initial static situation at $t = 0$, we need to estimate the time t such that both of the populations in competence are numerically equal.

Such estimation of the time t depends on the size of tumor and we have selected the optimal scenario, the one where the state of evolution of the tumor can be detected in a threshold where imaging based on magnetic resonance is in its better resolution. In addition to that, we want to suggest a mechanism.

For example, we can propose periodic scanning of the chest of a woman, or the prostate of a man, by using 1.5 Tesla MR scanner at a spatial resolution of $117 \times 117 \times 300\,\mu$m [19] and with micro-CT whose spatial resolution reach cubes with $100 \times 100 \times 100\,\mu$m [20]. It would be necessary a system to save and recover files with old and new images, and techniques to compare them automatically. This can be done with software based on neural networks.

Clearly, several approaches could be cited because work is being carried out to detect cancer. For example, multiparametric magnetic resonance imaging is considered as a promising method for the detection of prostate cancer [21]. Besides, a planar type antenna is reportedly a useful design for detecting a cancerous tumor of 5 mm in size, in the early stages of development [22]. On the other hand, Barbara Blasiak et. al. [23] have published a recent review where they discuss several applications of nanomaterials for early and specific cancer detection and therapy. And so on. The important point here is that very small tumors should be considered.



Figure 2

To estimate t we choose a tumor whose diameter is $200\,\mu$m, and a typical cancer cell whose radius is $r_c = 4\,\mu$m. Then, the equation (3) gives us $N_c = 625$. If $\rho_{leu} = 5 \times 10^9 \frac{leukocytes}{\mu\,\mathrm{l}}$ we get

$$t = 854.28\,\mathrm{s},$$

and with $\rho_{leu} = 1.1 \times 10^{10} \frac{leukocytes}{\mu\,\mathrm{l}}$ we obtain

$$t = 310.65\,\mathrm{s},$$

so that the interval to get the assumed scenario is

$$310.65\,\mathrm{s} < t < 854.28\,\mathrm{s}\,.$$

This is of the order of 5 minutes to 14 minutes and 15 seconds. Since the more aggressive cancer cells have a doubling time rate of two days, a stationary situation where it is considered the same amount of cancer cells and lymphocytes is an acceptable option.

In our model, extracellular matrix is considered just as an empty space to be occupied, without taking into account that, due to its destruction by the tumor, it is active in delivering nutrients to be used in the expansion of malignant cells.

A. Rate growth

1. Cancer cells reproduction speed

The potential doubling time is defined as the time necessary to double the number of proliferating tumor cells. According to the reference [24], the index named as potential doubling time (T_{pot}) is evaluated by using a linear regression such that a straight line is fitted to write the number of cells N as follows:

$$N = A + Be^{K_p t},$$

where K_p is named the rate constant of cell production.

The number of counted cells $N(t_1) = N_1$ and $N(t_2) = N_2$, with $t_2 > t_1$, are fixed as follows $N_1 = 10^3$ and $N_2 = 2 \times 10^3$, so that $T_{pot} = t_2 - t_1$. Then, we have

$$T_{pot} = \frac{1}{K_p} \log\left(\frac{2000 - A}{B}\right)$$

Taking $A = 0$, we write down

$$T_{pot} = \frac{1}{K_p} \log(2)$$

The next data can be found in (see Table 1 at [24])

tumor line	Origin	T_{pot} days (*)	T_{pot} days (**)
FaDu	SCC of pharynx	2.0 ± 0.2	1.3 ± 0.1
HCT15	Human colon adenocarcinoma	2.5 ± 0.1	2.2 ± 0.1
STS26T	Schwannoma (soft tissue sarcoma)	2.5 ± 0.2	2.4 ± 0.2
U87	Glioblastoma multiforme	3.9 ± 0.3	2.5 ± 0.2
SCC21	SCC	5.9 ± 0.3	2.9
HGL9	Glioblastoma multiforme	6.2 ± 0.3	3.9 ± 0.3
U251-MG	Glioblastoma multiforme	7.5 ± 0.5	10.5 ± 1.4

Table 1

where data marked with (*) are obtained with one of the methods described in the last reference (named first method cytokinesis block), and data marked with (**) are found by using another method explained in the same reference (named there as second method IdUrd).

Then, we have evaluated the next data for the rate constant of cell production, K_p, based in the expression: $K = \frac{\log(2)}{T_{pot}}$:

T_{pot} $(days)$	K_p $(days^{-1})$
1	0.693147
1.5	0.462098
2	0.346574
2.5	0.277259
3	0.231049
3.5	0.198042
4	0.173287
4.5	0.154033
5	0.138629
5.5	0.126027
6	0.115525
6.5	0.106638
7	0.099021
7.5	0.0924196
8	0.0866434

Table 2

Here, K_p plays the same role as the parameter b_1 (to be introduced ahead). So, we have assumed that an aggressive cancer tumor will be such that

$$b_1 = 0.35$$

where one cell produces a new one each two days.

B. Lymphocytes reproduction speed

According to reference [25]: "In healthy, HIV-1 seronegative subjects, $CD4^+$ T cells had half-lives of 87 days and 77 days, respectively, with absolute production rates of 10 $CD4^+ \frac{Tcells}{\mu l}$ per day and 6 $CD8^+ \frac{Tcells}{\mu l}$ per day."

Then, starting from 1, a sequence obtained by adding the number 6 during 77 times, reaches the value 463. If we assume an exponential growth, it must be a transition rate b_2 given by

$$b_2' = \frac{1}{77} \log (463) = 0.0797107,$$

for $CD4^+$ lymphocytes, while a sequence such that the number 10 is added 88 times give us

$$b_2'' = \frac{1}{88} \log (881) = 0.0770575,$$

for $CD8+$ lymphocytes. Therefore, we have chosen the value

$$b_2 = 0.078$$

for our simulations.

In normal conditions, a balance in the number of lymphocytes is found if it is assumed that apoptosis is $d_2 = 0.078$, too.

C. The model and a summary of a first analytical approach

1. How transition rates are built

Our model for the tumor is a space where there are Ω small boxes, with three categories for them: empty, occupied by a cancer cell, and occupied by a lymphocyte; so that there are M boxes occupied by lymphocytes, N boxes occupied by cancer cells, and $\Omega - M - N$ empty boxes. This is a collection to be treated as a big recipient with Ω balls, with three possible colors: a) a blue ball corresponds to an empty box, b) a white ball corresponds to a lymphocyte, and c) a black ball corresponds to a cancer cell. Events to be considered are classified in three groups: 1) to get just one ball, 2) to find two balls, and 3) to obtain three balls from the big recipient.

We denote a white ball (lymphocyte) with the letter B, a black ball (cancer cell) as A, and a blue ball (empty space) as E.

- In the first group of events we have: $B \to E$ (death of a lymphocyte by apoptosis), and $A \to E$ (death of a cancer cell by artificial apoptosis).

- In the second group of events: $B+E \to B+B$ (birth of a lymphocyte), $B+A \to B+B$ (death of a cancer cell due to the presence of a lymphocyte, or specialized defense), $A + E \to A + A$ (birth of a cancer cell), $A + A \to A + E$ (death of a cancer cell by self-competence).

- In the third group we consider just one event: $A + A + B \to A + A + E$ (death of a lymphocyte due to weakness of the patient).

All of the events can occur with transition rates denoted as:

- Death rate (apoptosis rate) for lymphocytes: d_2, $(B \to E)$.

- Death rate (artificial apoptosis rate) for cancer cells: d_1, $A \to E$.

- Birth rate for lymphocytes: b_2, $(B + E \to B + B)$.

- Death rate for cancer cells; c_{12}, $B + A \to B + B$.

- Birth rate for cancer cells: b_1, $A + E \to A + A$.

- Death rate (self-competence) for cancer cells: c_{11}, $A + A \to A + E$.

- Death rate (weakness due to sickness) for lymphocytes: c_{21}, $A + A + B \to A + A + E$.

Transition rates are built by using elementary probability, they are presented in the right column of the Table 3.

event	transition rate
$B \to E$	$d_2 \frac{M}{\Omega}$
$A \to E$	$d_1 \frac{N}{\Omega}$
$B + E \to B + B$	$b_2 \frac{M(M-1)}{\Omega(\Omega-1)}$
$B + A \to B + B$	$c_{12} \frac{MN}{\Omega(\Omega-1)}$
$A + E \to A + A$	$b_1 \frac{N(\Omega-N-M)}{\Omega(\Omega-1)}$
$A + A \to A + E$	$c_{11} \frac{N(N-1)}{\Omega(\Omega-1)}$
$A + A + B \to A + A + E$	$c_{21} \frac{N(N-1)M}{\Omega(\Omega-1)(\Omega-2)}$

Table 3

It will be seen ahead that the transition $B + A \rightarrow B + B$ is very important because it involves death of a cancer cell due to the action of a lymphocyte. In this case there are two actions in one, it is the substitution of one A-cell by a B-cell. So, the number N diminishes in 1, while the number M increases in 1. It is considered here as a specialized response modeling the activation of the body defense system through a sequence of biochemical events, such that this kind of white blood cell can identify specific antigens through a molecule named TCR. It can recognize specific antigens and can act as a cytotoxic cell against specific malignant cells in a tumor in a very lethal way. This is the reason to name it as specialized defense.

2. Analytical approach based on van Kampen expansion

In [15] we have developed an analytical model by defining population densities as

$$n = \frac{N}{\Omega} = \psi + \frac{1}{\sqrt{\Omega}}\eta, \;\; m = \frac{M}{\Omega} = \phi + \frac{1}{\sqrt{\Omega}}\xi, \tag{9}$$

with (ψ, ϕ) the deterministic part, and (η, ξ) the random noise. Besides, we separated each transition rate in a way similar to the one presented now

$$D_M = d_2 \frac{M}{\Omega} = d_2\phi + \frac{1}{\sqrt{\Omega}} d_2\xi = \Omega D_M^{(1)} + \sqrt{\Omega} D_M^{(0)}. \tag{10}$$

Thus, a van Kampen expansion was done and it was possible to separate the problem in two of them. First, a deterministic one, where differential equations must be solved to know $(\psi(t), \phi(t))$. Second, a time dependent Ornstein-Uhlenbeck stochastic process, whose density probability function obeys a Fokker-Planck equation whose coefficients depend on the statistical properties of $\langle\psi\rangle$ and $\langle\phi\rangle$.

The general approach presented there gives us a pair of coupled ordinary differential equations for the deterministic part of the problem

$$\begin{aligned} \frac{d\langle\psi\rangle}{dt} &= f\left(\langle\psi\rangle, \langle\phi\rangle, \left\langle\psi^j\phi^k\right\rangle\right) \\ \frac{d\langle\phi\rangle}{dt} &= g\left(\langle\psi\rangle, \langle\phi\rangle, \left\langle\psi^j\phi^k\right\rangle\right) \end{aligned} \tag{11}$$

with $j,\, k = 1, 2$.

These equations can be studied numerically by assuming uncorrelation and very small standard deviations in the deterministic part. These hypotheses can be written as follows:

$$\langle\psi\phi\rangle \simeq \langle\psi\rangle\langle\phi\rangle, \;\; \left\langle\phi^2\right\rangle \simeq \langle\phi\rangle^2, \;\; \left\langle\psi^2\right\rangle \simeq \langle\psi\rangle^2 \tag{12}$$

Based in the analytical treatment, the next equations were found:

$$\frac{d\langle\psi\rangle}{dt} = b_1\langle\psi\rangle - (b_1 + c_{12})\langle\psi\rangle\langle\phi\rangle - (b_1 + c_{11})\left\langle\psi^2\right\rangle - Q_1(\langle\psi\rangle + \varepsilon\langle\phi\rangle)$$
$$\frac{d\langle\phi\rangle}{dt} = (b_2 - d_2)\langle\phi\rangle - b_2\langle\psi\rangle\langle\phi\rangle - b_2\left\langle\phi^2\right\rangle - c_{21}\left\langle\psi^2\right\rangle\langle\phi\rangle - Q_1(\langle\psi\rangle + \varepsilon\langle\phi\rangle)$$

We have solved numerically this system of coupled nonlinear differential equations and two basins were found: one where the patient survives (health basin) plus other where he dies. We have accepted these results because the well-known medical evidence is reproduced.

Besides, time evolution of the cancer cell density can be explored from the first equation. To do that, we write it as

$$\frac{d\langle\psi\rangle}{dt} = b_1\langle\psi\rangle\left\{1 - \frac{1}{K_L}\langle\phi\rangle - \frac{1}{K_c}\langle\psi\rangle\right\} - Q_1(\langle\psi\rangle + \varepsilon\langle\phi\rangle)$$

where

$$K_c = \frac{1}{1 + \frac{c_{11}}{b_1}}$$

and

$$K_L = \frac{1}{1 + \frac{c_{12}}{b_1}}$$

Logistic growth is the particular case where there is no chemotherapeutic treatment and lymphocytes are not present. For this reason we put $Q_1 = 0$, and $\langle\phi\rangle = 0$. Then

$$\frac{d\langle\psi\rangle}{dt} = b_1\langle\psi\rangle\left\{1 - \frac{1}{K_c}\langle\psi\rangle\right\}$$

and a stationary state can be reached because $\lim_{t\to\infty}\langle\psi\rangle_s = K_c$. Therefore K_c is the carrying capacity of the population of cancer cells.

However, lymphocytes are an important part of the system and they play a fundamental role in the defense of the patient. So that it is necessary to see what happens in the healthy basin. This can be explored by assuming a case where successful chemotherapeutic treatment has been applied and retired with good results. We put $Q_1 = 0$, and $\langle\phi\rangle_s \simeq 1$, because almost all the available spaces are occupied by lymphocytes. Now the solutions are

$$\langle\psi\rangle_s^{(1)} \simeq 0$$

and

$$\langle\psi\rangle_s^{(2)} \simeq K_c\left(1 - \frac{1}{K_L}\right) = -\frac{c_{12}}{b_1}$$

But densities cannot be negative, so that $\langle\psi\rangle_s^{(2)}$ is not acceptable. As a consequence, from a macroscopic point of view, like in medical diagnosis, health has been recovered.

However there is a hidden problem. In the stochastic case densities are

$$\psi = \langle\psi\rangle + \eta, \quad \phi = \langle\phi\rangle + \xi$$

Denoting the random fluctuations as $(\eta, \xi) = (q_1, q_2) = \vec{q}$, the time dependent Ornstein-Uhlenbeck process obeys the following Fokker-Planck equation

$$\frac{\partial \Pi(\vec{q}, t)}{\partial t} = -\sum_{\mu=1}^{2} \frac{\partial \left[A_\mu\left(\langle\psi\rangle, \langle\phi\rangle, \vec{q}\right) \Pi(\vec{q}, t)\right]}{\partial q_\mu} + \frac{1}{2}\sum_{\mu=1}^{2}\sum_{\nu=1}^{2} \frac{\partial^2 \left[D_{\mu\nu}\left(\langle\psi\rangle, \langle\phi\rangle, \vec{q}\right) \Pi(\vec{q}, t)\right]}{\partial q_\mu \partial q_\nu} \tag{13}$$

with

$$\{A_\mu\} = \begin{pmatrix} A_1 \\ A_2 \end{pmatrix} = \mathbf{L}\left(\langle\psi\rangle, \langle\phi\rangle\right) \vec{q} \tag{14}$$

the flux term and $\mathbf{L}\left(\langle\psi\rangle, \langle\phi\rangle\right)$ the matrix convection. The diffusion matrix is given as

$$\{D_{\mu\nu}\} = \begin{pmatrix} D_{11}\left(\langle\psi\rangle, \langle\phi\rangle\right) & D_{12}\left(\langle\psi\rangle, \langle\phi\rangle\right) \\ D_{12}\left(\langle\psi\rangle, \langle\phi\rangle\right) & D_{22}\left(\langle\psi\rangle, \langle\phi\rangle\right) \end{pmatrix} = \mathbf{D} \tag{15}$$

Since the random part depends on the deterministic one, the process is named a nonautonomous system. Correlations are defined as

$$\{\Xi_{\mu\nu}\} = \{\langle q_\mu q_\nu\rangle - \langle q_\mu\rangle \langle q_\nu\rangle\} = \mathbf{\Xi}, \tag{16}$$

and satisfy the differential equations written by van Kampen [26]:

$$\frac{d\mathbf{\Xi}}{dt} - \mathbf{L}\mathbf{\Xi} - \mathbf{\Xi}\mathbf{L} = \mathbf{D} \tag{17}$$

The solution to (13) is a Gaussian function given as

$$\Pi(\vec{q}, t) = \frac{1}{\sqrt{2\pi}\sqrt{\det \mathbf{\Xi}}} \exp\left\{-\frac{1}{2}\left[\vec{q} - \langle\vec{q}\rangle(t)\right] \cdot \mathbf{\Xi}^{-1}\left[\vec{q} - \langle\vec{q}\rangle(t)\right]\right\} \tag{18}$$

Using that $\Xi_{12} = \Xi_{21}$, the vector $\vec{z}$ is defined as

$$\vec{z} = \begin{pmatrix} \Xi_{11} \\ \Xi_{12} \\ \Xi_{22} \end{pmatrix}$$

and the system (17) can be written as

$$\frac{d\vec{z}}{dt} = \mathbf{A}\vec{z} + \vec{d}$$

with $\mathbf{A}$ a matrix whose components depend on time through the pair $\{\langle\psi\rangle, \langle\phi\rangle\}$. The trivector $\vec{d}$ contains the diffusion. This expression has been used to analyze the case $\langle\phi\rangle_s \simeq 1$ and $\langle\psi\rangle_s \simeq 0$, founding that the eigenvalues of the matrix $\mathbf{A}$ take positive values; then, the time-evolution of $z_i(t)$ is not bounded. This suggest that a possible noise-induced escape from health basin could be hidden here.

In summary, the analytical approach give us the next conclusions:

1. The deterministic part is divided in two basins: one of healthy patient, with final states near $(0, 1)$; and other one for death patients, such that the final state is near $(1, 0)$.

2. The random part is such that fluctuations could maintain instability in final states, such that healthy patients are in risk.

However, this analytical approach cannot help us to explore the last conclusion, because these time dependent Ornstein-Uhlenbeck stochastic processes are useful for small fluctuations, and since these goes like $\sim N^{-\frac{1}{2}}$, small populations result unreachable. So, we have to consider that this simulation approach is necessary to include any number of cancer cells and lymphocytes and without the hypothesis (12).

D. Algorithm for computer simulation

Once transition rates and events are available, Doob and Gillespie algorithm can be applied to get the simulations [27]. This was done taking into account a software developed by Th. Newman [28, 29]. The original problem in Gillespie paper consists in a chemical system confined in a volume V and evolving on time, such that it can be specified by M state variables h_1, h_2, ..., h_M, with h_μ being the number of different molecular reactants combinations for each reaction R_μ. $(\mu = 1, ..., M)$. Obviously, there should be transition rates specified (please see [30]). In our paper, these transition rates are built by using elementary probability (see Table 3).

Gillespie approach considers a reaction probability density function $P(\tau, \mu)$, such that $P(\tau, \mu)\, d\tau$ is the probability, at time τ, that a reaction will occur in the interval $(t+\tau, t+\tau+d\tau)$. He followed a reasoning similar to the one expressed to study the probability of collisions in gases [31]. First, he considered the probability $P_0(\tau)$ that no reaction occurs in the interval $(t, t+\tau)$. Second, it was taken into account the probability $h_\mu c_\mu d\tau$, to first order in $d\tau$, that a reaction R_μ occurs in the interval $(t+\tau, t+\tau+d\tau)$. If the no overlapping intervals are statistically independents, the probability that there is no reaction in the interval $(t, t+\tau)$, but there is a reaction at $(t+\tau, t+\tau+d\tau)$, is

$$P(\tau, \mu)\, d\tau = P_0(\tau)\, h_\mu c_\mu d\tau \tag{19}$$

Then, he found that the density probability $P(\tau, \mu)$ is given as

$$P(\tau, \mu) = h_\mu c_\mu e^{-\sum_{\nu=1}^{M} h_\nu c_\nu \tau} \tag{20}$$

As a consequence, a stochastic process described by the transitions given at Table 3 can be simulated, according to Gillespie, with the following algorithm. Here it is named as a one urn model of no spatial cancer cells and lymphocytes:

Step = 0: Initialization

The number Ω of objects in the urn is generated. This is the number of sites in the line of battle of our paper.

The number of realizations N_0 is specified. $N_0 = 1$ in the historical mode, or $N_0 \sim 10^4$ in the final mode.

Transition rates are introduced: $\sigma_i,\ i = 1, .., M$, with M the number of interactions between two species.

Initial time $t = 0$ is set.

The initial number of cancer cells $N_A(0)$, and lymphocytes $N_B(0)$, are specified. Store (t, N_A, N_B).

The variable $sigma_sum = 0$ is set.

Step = 1: Iteration

1. Produces an actualization of the variable $sigma_sum$ as follows:

$$sigma_sum = \sum_{i=1}^{M} \sigma(i) \tag{21}$$

2. Generates two random numbers r_1 and r_2, with homogeneous probability in $[0, 1]$.

3. Creates time increment
$$\tau = \frac{1}{sigma_sum} \ln\left(\frac{1}{r_1}\right) \tag{22}$$
This gives us a random τ with exponential distribution.

4. Actualizes the time $t \to t + \tau$.

5. Random number r_2 is used to choose one of the M interactions.

6. Actualizes N_A and N_B according to the event chosen in 5.

7. Stores $(t + \tau, N_A, N_B)$ and go to 1.

III. RESULTS AND DISCUSSION

Our simulation of the line of battle in an avascular tumor, described above, was developed considering the following fixed parameters: $b_1 = 0.35$, $b_2 = d_2 = 0.078$, and c_{12}, c_{21}, c_{11}; and d_1 changing such that real behavior reproduced in medical practice can be simulated. However, since we are dealing with the simulation in a line of battle, an estimation of real time cannot be obtained at this stage of the model. We must recognize that this is a problem under consideration right now, for example, some authors have presented reasons to think that development of big tumors is exponential at first, but polynomial after that [32].

The simulation produces the next results:

A. Checking the algorithm

At first, the approach was checked by working with $b_1 = d_1 = 0.35$, and the others parameters equal to zero. Initial conditions where: $\Omega = 6250$, $N\,(t = 0) = 625$ and $M\,(t = 0) = 1$. Algorithm was run in two modes: in the first one the time evolution is saved to a file (historical mode), and in the second one just the final data are saved to a file once a time has been reached (final results mode). The historical mode is presented in figure 3.



Figure 3

In the final results mode 10^4 data were generated, then, mean and standard deviation were evaluated to obtain:

$$\langle N \rangle = 591.625, \qquad \sigma_N = 23.9466,$$

where $\langle N \rangle$ and σ_N are taken on the sample of data obtained.

A similar work was done to see the behavior of lymphocytes when $b_2 = d_2 = 0.078$, and the rest of parameters equal to zero. Here the initial conditions were: $\Omega = 6250$, $N\,(t = 0) = 1$, and $M\,(t = 0) = 625$. The historical mode gives us a graph presented in figure 4.



Figure 4

After that, the final results mode was used to generate 10^4 data. Mean and standard deviation gave us:

$$\langle M \rangle = 617.166, \qquad \sigma_M = 12.0828$$

B. Development without specialized defense

Here we will consider two different systems. In one of them, sentinel macrophages are activated when tissue homeostasis is perturbed, so that soluble mediators are released, like cytokines, chemokines, matrix remodeling proteases and reactive oxygen species, bioactive mediators such as histamine to induce mobilization and infiltration of additional leukocytes into damaged tissue. The other one is a more sophisticated adaptive immune system developed through direct interaction with mature antigen-presenting cells where the adaptive immune cells are involved, like B lymphocytes, $CD4^+$ helper T lymphocytes and $CD8^+$ cytotoxic lymphocytes [33]. Both systems, specialized, and non-specialized defense, are simulated ahead.

First we simulate the case of a sick patient without medical treatment, this is done by taking the following initial conditions: $\Omega = 6250$, $N\left(t=0\right) = M\left(t=0\right) = 625$. Regime of a sick person without medical attention was simulated by using the parameters: $b_1 = 0.35$, $b_2 = d_2 = 0.078$, with $c_{12} = c_{21} = c_{11} = d_1 = 0$. Historical mode gives us the graph shown in figure 5.



Figure 5

Using the final data mode, we developed 10^4 realizations to evaluate the mean and the standard deviation of cancer cells in the time needed to take the number of lymphocytes down to zero. This is

	Number	Volume $(\mu\text{m})^3$
$\langle N \rangle$	6248.72	1.67517×10^6
σ_N	0.596	1.598

Average time and its standard deviation is presented in algorithmic time and its translation to days is done by dividing by the number of available spaces $\Omega = 6250$.

	Algorithmic time	days
$\langle t \rangle$	537 657	86.02
σ_t	63 530	10.16

This can be interpreted in the sense that cancer cells prevail because the cancer cells of the line of battle are successful to produce, in 86 days, a growing tumor whose extension is added in a volume of $1.67517 \times 10^6\,(\mu\text{m})^3$. Obviously the action of lymphocytes is not enough.

C. Development with immune response (specialized defense)

The immune specialized response is simulated by considering the same initial conditions used in the previous subsection. It is a regime of a sick person without medical attention but with good immune response, and the parameters used were: $b_1 = 0.35$, $b_2 = d_2 = 0.078$, with $c_{12} = 1 \times 10^{-5}$, and $c_{21} = c_{11} = d_1 = 0$.

Historical mode gives us the graph shown in figure 6:



Figure 6

We find that by increasing the specialized defense against cancer cells, the lymphocytes prevail on the line of battle in just 300 unites of algorithmic time. If one has 25 layers of cancer cells, 7500 units of algorithmic time would be enough. This result suggests three reflections:

1. According to this model, colonies of cancer cells could appear on the organism frequently, but they would be destroyed before a tumor can reach a critical radius to start metastasis.

2. A tumor grows enough, and appears with a critical radius, due to the absence of a specialized defense where the enemies (cancer cells) are clearly identified and a specific kind of lymphocytes are produced and directed against.

3. A tumor with a critical radius appears just when a barrier is opposed to blood flux and lymphocytes do not get touch with cancer cells.

The final data mode was developed by simulating 10^4 realizations to evaluate the mean and the standard deviations of lymphocytes in the time needed to take the number of cancer cells down to zero. It was found that

	Number
$\langle M \rangle$	1251.34
σ_M	4.35

	Algorithmic time for 25 layers	days
$\langle t \rangle$	14840.9	2.374
σ_t	2474.47	0.396

In attention to the third reflection, we can cite a review by Trédan et. al. [34]. They have discussed that the effectiveness of drug therapy is impaired by limited delivery of drugs to some regions of tumors. So, we can think that similar results should be true for the action of specialized defense of the body, such that if cancer cells survive, it is because they are not in touch with lymphocytes.

D. Development with specialized defense and a weak patient

We consider the same condition in immune specialized response, but now with a patient whose production of lymphocytes is diminished due to proliferation of cancer cells. This was simulated by using the parameters: $b_1 = 0.35$, $b_2 = d_2 = 0.078$, $c_{12} = 1 \times 10^{-5}$, and $c_{21} = 1$, while $c_{11} = d_1 = 0$.

Historical mode gives us the graph of figure 7.



Figure 7

It is found that specialized defense against cancer cells gives good results, even in the case of weakness in patients. This is corroborated by using the final data mode. We simulate 10^4 realizations to obtain the mean and the standard deviations of lymphocytes in the time

needed to take the number of cancer cells down to zero. The results are

	Number
$\langle M \rangle$	1251.34
σ_M	4.35

	Algorithmic time for 25 layers	days
$\langle t \rangle$	14858	2.378
σ_t	2507.93	0.401

E. Development with a lot of lymphocytes but non-specialized defense

This is a strategy where reproduction rate of lymphocytes grow but in a general sense, without acting through the transition: $B + A \to B + B$. This is done with the following values of the parameters: $b_1 = 0.35$, $b_2 = 1$, $d_2 = 0.078$, $c_{12} = c_{21} = c_{11} = d_1 = 0$. Results are shown in figure 8.



Figure 8

With the parameters $b_1 = 0.35$, $b_2 = 1.5$, $d_2 = 0.078$, $c_{12} = c_{21} = c_{11} = d_1 = 0$, the graph obtained is shown in figure 9.



Figure 9

And with the parameters $b_1 = 0.35$, $b_2 = 2$, $d_2 = 0.078$, $c_{12} = c_{21} = c_{11} = d_1 = 0$, the results are shown in figure 10.



Figure 10

We found that even with a big amount of lymphocytes, good results are not reached. The absence of specialized lymphocytes produces fatal results.

F. Strategy based on anti-angiogenic drugs. self-competition in cancer cells

A new broad family of anticancer drugs has been approved in recent years. These are angiogenesis inhibitors administrated to avoid the building of new blood vessels going from

the main blood flow to the region where the tumor has born. They can inhibit the production of angiogenic proteins, neutralize angiogenic proteins or inhibit receptors where these proteins are received. Some drugs induce endothelial cell apoptosis.

The general effect of these new drugs is to restrict, in some way, the flow of oxygen and nutrients to the tumor. So, this is analog to the situation of a colony of bacteria in a recipient with a finite capacity of oxygen and nutrients. This is modeled in an approach named "logistic growth", where a quadratic term is added ad hoc to introduce a control in the, otherwise, exponential growth. The number of bacteria in the recipient is stabilized because they are competing for food.

This is the case in cancer cells when they are in the core of a tumor, so that blood flow does not arrive there and necrotized tissue appears as a consequence. However, in the line of battle is totally different, because there is a lot of blood there, so that reproduction is possible. Our idea is to avoid all the complex details involved in the process produced by anti-angiogenic drugs, to model their effect as one where oxygen and nutrients are not enough, even in the surface of the tumor. So, the effect of antiangiogenic drugs is modeled through the constant c_{11}, as self-competition between cancer cells looking for oxygen and nutrients running out. It is the transition: $A + A \to A + E$.

Working with the parameters $b_1 = 0.35$, $b_2 = d_2 = 0.078$, $c_{12} = c_{21} = d_1 = 0$, and $c_{11} = 1 \times 10^{-5}$, and using the historical mode, we found the graph shown in figure 11.



Figure 11

Figure 11 is very important because contains two interesting results:

First: we can see that number of cancer cells in the line of battle goes to zero, however, the amount of lymphocytes goes down to a very dangerous level. This is an unexpected consequence because any transition rate of this model is considering side effects. We have found in the literature that anti-angiogenic therapy could cause several toxicities and biological effects, please see reference [35].

Second: cancer cells go to zero after a very long time with very small random fluctuations. At a first glance, medical treatment can be retired because macroscopic manifestations cannot be detected. However, this is precisely the regime that we could not solve with our analytical approach. A regime with unbounded standard deviations. We will see in the next subsection what happens in this case.

G. Released patients under macroscopic considerations

By observing figure 11 we could think that it is better to withdraw a treatment when the number of lymphocytes is of the order of 400, before they reach a dangerous level. We have modeled that option by starting from the initial conditions $N\left(t=0\right)=3$ and $M\left(t=0\right)=625$, with the parameters $b_1=0.35$, $b_2=d_2=0.078$, with $c_{12}=c_{21}=c_{11}=d_1=0$. The historical mode gives us the results shown in figure 12.



Figure 12

Even for small values of the number of cancer cells, we found fatal results. So, an important prediction of the model is that there is only one option: to take the number of cancer cells down to zero.

In this dormant state there is no clinical or radiological evidence, because the number of malignant cells is very low, thus its reproduction and organic dissemination rates are low too. But there already are mutations associated with malignant processes that are detected with ultrasensitive molecular methods. See for example [36].

H. Induced apoptosis in cancer cells

Induced apoptosis of cancer cells is introduced with the constant d_1 in order to model the action of the Cuban drug Vidatox 30 CH, as reported by A. Díaz et. al. [37]. They wrote that venom of the scorpion Rhopalurus Junceus caused the cellular death through the apoptosis in tumor cells. It is the transition $A \to E$, and was simulated with the parameters $b_1 = 0.35$, $b_2 = d_2 = 0.078$, with $c_{12} = c_{21} = c_{11} = 0$, and $d_1 = \{0.1, 0.2, 0.3, 0.4, 0.5\}$. The historical mode gives us the results shown in figures 13 to 17.



Figure 13



Figure 14



Figure 15



Figure 16



Figure 17

We have found that induced apoptosis gives us good results provided that the parameter takes higher values. It can be seen that the amount of lymphocytes is higher than 400 with the values of the parameter $d_1 = 0.4, 0.5$.

I. Combining anti-angiogenic drugs and induced apoptosis in cancer cells

Now we can review what happen if anti-angiogenic and inducer apoptosis drugs are combined.

The historical mode gives us the results shown in figure 18.



Figure 18

Here the number of cancer cells goes to zero, when the number of lymphocytes is higher than the obtained in the strategy based on anti-angiogenic drugs. A specific detail was analyzed by using the final data mode: we developed 10^4 realizations with the parameters $b_1 = 0.35$, $b_2 = d_2 = 0.078$, with $c_{12} = c_{21} = 0$, and $c_{11} = 1 \times 10^{-5}$, $d_1 = 0.1$. As was presented above, the results with $c_{11} = 1 \times 10^{-5}$ are positive, but with a dangerous amount of lymphocytes. Besides, $d_1 = 0.1$ does not produce good results. On the contrary, if both of them are combined, the number of cancer cells goes to zero with the following mean and standard deviations for time and number of lymphocytes:

	Number
$\langle M \rangle$	501.18
σ_M	80.26

	Algorithmic time for 1 layer
$\langle t \rangle$	218320
σ_t	170917

It can be seen that standard deviation is too large, 78.29% of the mean. As we have found before, this kind of random behavior is higher in the change from fatal results to healthy patients. To review that, we developed 10^4 realizations in the final data mode, with the parameters: $b_1 = 0.35$, $b_2 = d_2 = 0.078$, with $c_{12} = c_{21} = 0$, but $c_{11} = 1 \times 10^{-4}$, $d_1 = 0.2$.

After the statistical analysis we found

	Number
$\langle M \rangle$	613.65
σ_M	15.86

	Algorithmic time for 1 layer
$\langle t \rangle$	14663.1
σ_t	8941.89

The number of lymphocytes is higher in 22.44% than in previous case; besides, time is shorter and its standard deviation has diminished to 60.98% of the mean time.

Then, one important conclusion of this work is that efficiency is enhanced with a combination of anti-angiogenic drugs plus a system based in artificial apoptosis of cancer cells.

While some reticence against induced-apoptosis in cancer cells exists, as an option to obtain successful anti-cancer drugs, it must be recognized that it is a mechanism strongly considered right now. Favorable opinions can be found in [38].

IV. CONCLUSIONS

The results obtained in this work allow us to discuss the following:

- This model predicts that cancer can relapse from a very small number of cancer cells due to the existence of unbounded standard deviations.
- Specialized immune response of a living being is definitely crucial in fighting cancerous tumors.
- Even in the case of a weakened patient, sufficient production of specialized leukocytes may be decisive in the survival of the organism.
- When the body does not have specialized leukocytes, its capacity to deal with the problem of a cancerous tumor is very limited, and the prognosis is unfortunately death.
- The use of anti-angiogenic drugs is a strategy that can be used to remove cancerous tumors. However, they also affect the rest of the body; they can weaken and place in

a fragile state to the patient before the attack of other possible diseases. Furthermore, if the cancer cells are not eliminated, there is a high probability that they re-grow in number, and again the result is fatal.

- A strategy based on a novel drug that causes apoptosis of cancer cells shows great potential in fighting cancerous tumors, but it also produces some weakening of the body.

- The combination of strategies seems to be a better alternative because it could produce a very rapid decrease in cancer cells, reducing the amount of medication to be administered and therefore would be less side effects.

V. REFERENCES

[1] R. H. Thomlinson and L. H. Gray, "The histological structure of some human lung cancers and the possible implications for radiotherapy", *British Journal of Cancer,* vol. 9, pp. 539-549, 1955.

[2] W. Duchting and G. Dehl, "Spread of cancer cells in tissue: modeling and simulation", *International Journal of Bio-Medical Computing*, vol. 11, pp. 175-195, 1980. W. Duchting and T. Vogelsaenger, "Three-dimensional pattern generation applied to spheroidal tumor growth in a nutrient medium", *International Journal of Bio-Medical Computing*, vol. 12, pp. 377-392, 1981.

[3] R. Lefever and T. Erneaux, "On the growth of cellular tissues under constant and fluctuating environmental conditions" in *Nonlinear Electrodynamics in Biological Systems*, W. R.Adey and A. F. Lawrence, Eds., pp. 287-305, Plenum Press, 1984.

[4] J. A. Adams, "A simplified mathematical model of tumor growth", *Mathematical Biosciences*, vol. 81, pp. 229-244, 1986. J. A. Adams, "A mathematical model of tumor growth. II. Effects of geometry and spatial nonuniformity on stability, *Mathematical Biosciences*, vol. 86, pp. 183-211, 1987. J. A. Adams, "A mathematical model of tumor growth. III. Comparison and experiment", *Mathematical Biosciences*, vol. 86, pp. 213-227, 1987.

[5] T. E. Wheldon, *Mathematical Models in Cancer Research*, Adam Hilger, 1988. R. M. Sutherland, "Cell and environment interactions in tumor microregions: the multicell spheroid model", *Science*, vol. 240, pp. 177-184, 1988).

[6] Y. N. Gavhane, A. S. Shete, A. K. Bhagat, V. R. Shinde, K. K. Bhong, G. A. Khairnar, A. V. Yadav, "Solid tumors: facts, challenges, and solutions", *International Journal of Pharma Sciences and Research* (IJPSR), vol. 2, pp. 1-12, 2011.

[7] R. K. Jain, "Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors", *Cancer Research* (Suppl.), vol. **50**, pp. 814-819, 1990.

[8] R. Rosell, J. Gomez-Codina, C. Camps, J. Maestre, J. Padille, A. Canto, J. L. Mate, S. Li, J. Roig, A. Olazabal, M. Canela, A. Ariza, Z. Skacel, J. Morera-Prat, A. Abad, "A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer", *The New England Journal of Medicine*, vol. 330, pp. 153-158, 1994.

[9] T. Roose, S. J. Chapman, P. K. Maini, "Mathematical Models of Avascular Tumor Growth", *SIAM Review*, vol. 49, pp. 179-208, 2007.

[10] E. J. Koay, M. J. Truty, V. Cristini, R. M. Thomas, R. Chen, D. Chatterjee, Y. Kang, P. R. Bhosale, E. P. Tamm, C. H. Crane, M. Javle, M. H. Katz, V. N. Gottumukkala, M. A. Rozner, H. Shen, J. E. Lee, H. Wang, Y. Chen, W. Plunkett, J. L. Abbruzzese, R. A. Wolff, G. R. Varadhachary, M. Ferrari, J. B. Fleming, "Transport properties of pancreatic cancer describe gemcitabine delivery and response", *The Journal of Clinical Investigation,* vol 124, pp. 1525-1536, 2014.

[11] M. E. Edgerton, Y.-Li Chuang, P. Macklin,, W. Yang, E. L. Bearer, V. Cristini, "A novel, patient-specific mathematical pathology approach for assessment of surgical volume: Application to ductal carcinoma in situ of the breast", *Analytical Cellular Pathology,* vol 34, pp. 247–263, 2011

[12] J. Pascal, E. L. Bearer, Z. Wang, E. J. Koay, S. A. Curley, V. Cristini, "Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements", *PNAS*, vol. 110, pp. 14266–14271, 2013

[13] M. V. Blagosklonny, "Antiangiogenic therapy and tumor progression", *Cancer Cell*, vol. 5, pp. 13-17, 2004.

[14] Y. Shaked, E. Henke, J. Roodhart, P. Mancuso, M. Langenberg, M. Colleoni, L. G. Daenen, S.

Man, P. Xu, U. Emmenegger, T. Tang, Z. Zhu, L. Witte, R. M. Strieter, F. Bertolini, E. Voest, R. Benezra, R. S. Kerbel, "Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents", *Cancer Cell*, vol. 14, pp. 263–273, 2008.

[15] A. Castellanos-Moreno, J. Argüelles-Campoy, A. Corella-Madueño, S. Gutiérrez-López y R.A. Rosas-Burgos, "Fluctuaciones aleatorias en la acción quimioterapéutica sobre tumores cancerosos", *Revista Mexicana de Fisica*, vol. 55, pp. 38-50, 2009.

[16] P. Macklin, S. McDougall, A. R. A. Anderson, M. A. J. Chaplain, V. Cristini, J. Lowengrub, "Multiscale modelling and nonlinear simulation of vascular tumor growth", *Journal of Mathematical Biology*, vol. 58, pp. 765-798, 2009.

[17] These are traditional data in courses about anatomy and physiology, see for example: http://www.rci.rutgers.edu/˜uzwiak/AnatPhys/Blood_Vessels.html

[18] K. Yamauchi, M. Yang, P. Jiang, N. Yamamoto, M. Xu, Y. Amoh, K. Tsuji, M. Bouvet, H. Tsuchiya, K. Tomita, A. R. Moossa, R. M. Hoffman, "Real-time *In vivo* Dual-color Imaging of Intracapillary Cancer Cell and Nucleus Deformation and Migration", *Cancer Research*, vol. 65, pp. 4246-4252, 2005.

[19] S. Majumdar, M. Kothari, P. Augat, D. C. Newitt, T. M. Link, J. C. Lin, T. Lang, Y. Lu, H. K. Genant, "High-resolution magnetic resonance imaging: three-dimensional trabecular bone architecture and biomechanical properties", *Bone*, vol. 22, pp. 445-454, 1998.

[20] C. T. Badea, E. Bucholz, L. W. Hedlund, H. A. Rockman, G. A. Johnson, "Imaging Methods for Morphological and Functional Phenotyping of the Rodent Heart", *Toxicologic Pathology*, vol. 34, pp. 111-117, 2006.

[21] S. Sankineni, M. Osman, P. L. Choyke, "Functional MRI in Prostate Cancer Detection", *BioMed Research International,* vol 2014, Article ID 590638, 2014

[22] S. S. Tiang, M. S. Hathal, N. S. Nik Anwar, M. F. Ain, M. Z. Abdullah, "Development of a Compact Wide-Slot Antenna for Early Stage Breast Cancer Detection Featuring Circular Array Full-View Geometry", *International Journal of Antennas and Propagation*, vol 2014, Article ID 309321, 2014

[23] B. Blasiak, F. C. J. M. van Veggel, B. Tomanek, "Applications of Nanoparticles for MRI Cancer Diagnosis and Therapy", *Journal of Nanomaterials,* vol 2013, Article ID 148578, 2013

[24] L. Hlatky, M. Olesiak, P. Hahnfeldt, "Measurement of Potential Doubling Time for Human

Tumor Xenografts Using the Cytokinesis-Block Method", *Cancer Research*, vol. **56**, pp. 1660-1663, 1996.

[25] M. Hellerstein, M. B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, S. Deeks, J. M. McCune, "Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans", *Nature Medicine*, vol. 5, pp. 83-89, 1999.

[26] N. G. van Kampen, *Stochastic processes in physics and chemistry*, North-Holland, 1992.

[27] D. Gillespie, *Markov Processes* (*an introduction for physical scientists*), Academic Press, San Diego, 1992.

[28] A. J. McKane, T. J. Newman, "Stochastic models in population biology and their deterministic analogs", *Physical Review E*, vol. 70, article 041902, 2004.

[29] Personal communication.

[30] D. Gillespie, "A general method for numerically simulating the stochastic time evolution of coupled chemical reactions", *Journal of Computational Physics*, vol. 22, pp. 403-434, 1976.

[31] F. Reif, *Fundamentals of Statistical and Thermal Physics*, McGraw-Hill, New York, 1965.

[32] F. B. Brikci, J. Clairambault, B. Perthame, "Analysis of a molecular structured population model with possible polynomial growth for the cell division cycle", *Mathematical and Computer Modelling*, vol. 47, pp. 699–713, 2008.

[33] K. E. de Visser, A. Eichten, L. M. Coussens, "Paradoxical roles of the immune system during cancer development", *Nature Reviews Cancer*, vol. 6, pp. 24-37, 2006.

[34] O. Trédan, C. M. Galmarini, K. Patel, I. F. Tannock, "Drug Resistance and the Solid Tumor Microenvironment", *Journal of the National Cancer Institute*, vol. 99, pp. 1441-1454, 2007.

[35] H.-C. Wu, C.-T. Huang, D.-K. Chang, "Anti-angiogenic therapeutic drugs for treatment of human cancer", *Journal of Cancer Molecules*, vol. 4, pp. 37-45, 2008.

[36] A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. C. W. Eclov, L. A. Modlin, C. L. Liu, J. W. Neal, H. A. Wakelee, R. E. Merritt, J. B. Shrager, B. W. Loo Jr, A. A. Alizadeh, M. Diehn, "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage", *Nature Medicine* (2014) doi:10.1038/nm.3519

[37] A. Díaz, L. Morier, H. Rodríguez, Y. Caballero, "Citotoxicidad del veneno del escorpión cubano Rhopalurus junceus y sus fracciones sobre líneas celulares humanas", *LABIOFAM*, vol. 1, pp. 12-18, 2010.

[38] M. Z. Majid, Z. M. Zaini, F. A. Razak, "Apoptosis-Inducing effect of three medicinal plants on oral cancer cells KB and ORL-48", *The Scientific World Journal,* vol 2014, Article ID 125353. And several works presented in: 8th Swiss Apoptosis Meeting Langhans Auditorium, Institute of Pathology University of Bern, Bern, September 10 - 12, 2014, http://pharmacology.unibe.ch/SAM2014/pdf/SAM2014_Abstracts.pdf. Against apoptosis as an option was presented in: Editorial, Apoptosis: a clinical perspective, http://www.nature.com/nrd/journal/v7/n12/pdf/nrd2756.pdf.